Astellas announces Japan restructuring and workforce cuts

23 May 2018

Japanese drugmaker Astellas (TYO: 4503) has announced a restructuring of operations in its home country, involving a reduction of the workforce by around 600.

The Tokyo-based firm has attributed the cost-saving initiatives as being aimed at realizing its newly-announced Strategic Plan 2018. This targets the building and optimizing of Astellas’ organizational capabilities and the continuing pursuit of operational excellence, the company says in a statement.

“Accordingly, Astellas will restructure all operations, including R&D and Sales & Marketing, and its group companies in Japan,” the statement adds.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK